Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer

This is an investigator initiated trial to assess the efficacy and safety of a GCC-targeting CAR-T therapy (REVO-UWD-01) in the metastatic colorectal cancer. It also aims to explore the feasibility of using a novel universal CAR-T cell platform.

Trial Details

NCT ID
NCT06653010
Phase
EARLY_PHASE1
Sponsor
Wondercel Biotech (ShenZhen)
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Universal CAR-T cells injection for treating mCRC
Locations (sample)
  • Shenzhen, Guangdong, China|22.54554,114.0683
  • Xi'an, Shaanxi, China|34.25833,108.92861

Key Eligibility Criteria

  • Age: ≥18 years and ≤75 years old.
  • Pathological Diagnosis: Pathologically confirmed metastatic colorectal cancer with radiographically confirmed metastatic lesions (e.g., CT or MRI).
  • GCC Expression: Tumor lesions assessed by immunohistochemistry (IHC) showing GCC expression ≥1+ in ≥50% of the area (randomly select at least 5 fie…
  • Measurable Lesions: At least one measurable lesion per RECIST 1.1 criteria; measurable lesions should not have received prior radiotherapy or inter…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →